• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    5/26/22 8:08:50 AM ET
    $AVDL
    $BJDX
    $CNCE
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AVDL alert in real time by email

     

    Gainers

    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 71.6% to $1.09 during Thursday's pre-market session. The market value of their outstanding shares is at $30.5 million.
    • Reshape Lifesciences (NASDAQ:RSLS) stock rose 15.49% to $0.82. The company's market cap stands at $2.8 million. As per the news, the Q1 earnings report came out 3 days ago.
    • Monopar Therapeutics (NASDAQ:MNPR) shares moved upwards by 14.81% to $2.48. The company's market cap stands at $31.2 million.
    • Liquidia (NASDAQ:LQDA) shares moved upwards by 9.04% to $3.98. The market value of their outstanding shares is at $256.0 million.
    • Evelo Biosciences (NASDAQ:EVLO) shares increased by 8.88% to $1.96. The company's market cap stands at $105.1 million.
    • Concert Pharma (NASDAQ:CNCE) stock increased by 8.11% to $5.06. The company's market cap stands at $183.8 million.

    Losers

    • NRX Pharmaceuticals (NASDAQ:NRXP) shares decreased by 39.9% to $0.83 during Thursday's pre-market session. The market value of their outstanding shares is at $55.3 million.
    • Avadel Pharmaceuticals (NASDAQ:AVDL) shares decreased by 23.08% to $2.6. The market value of their outstanding shares is at $153.4 million.
    • Genocea Biosciences (NASDAQ:GNCA) stock decreased by 8.7% to $0.08. The company's market cap stands at $4.9 million.
    • Motus GI Hldgs (NASDAQ:MOTS) shares declined by 8.34% to $0.28. The company's market cap stands at $15.1 million.
    • Verrica Pharmaceuticals (NASDAQ:VRCA) stock declined by 7.97% to $1.85. The company's market cap stands at $50.9 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) shares decreased by 7.41% to $1.0. The company's market cap stands at $20.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AVDL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVDL
    $BJDX
    $CNCE
    $EVLO

    CompanyDatePrice TargetRatingAnalyst
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Monopar Therapeutics Inc.
    $MNPR
    11/14/2025Strong Buy → Outperform
    Raymond James
    Monopar Therapeutics Inc.
    $MNPR
    11/10/2025$115.00Outperform
    Leerink Partners
    Avadel Pharmaceuticals plc
    $AVDL
    10/23/2025$20.00Buy → Neutral
    H.C. Wainwright
    Liquidia Corporation
    $LQDA
    10/20/2025$31.00Overweight
    Wells Fargo
    Monopar Therapeutics Inc.
    $MNPR
    10/13/2025$125.00Overweight
    Barclays
    Monopar Therapeutics Inc.
    $MNPR
    9/9/2025$87.00Buy
    BTIG Research
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    More analyst ratings

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CMO Rosenberg Noah L. bought $10,000 worth of shares (2,357 units at $4.24) (SEC Form 4)

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    11/25/25 7:00:16 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manning Paul B bought $17,505,157 worth of shares (4,126,142 units at $4.24) (SEC Form 4)

    4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)

    11/25/25 7:00:09 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

    WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to di

    3/5/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarterMore than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025Ended 2025 with $190.7 million in cash and cash equivalents, an increase of $33.2 million from the third quarterRecorded second consecutive quarter of profitability MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the full year ended December 31,

    3/5/26 6:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    SEC Filings

    View All

    SEC Form 10-K filed by Liquidia Corporation

    10-K - Liquidia Corp (0001819576) (Filer)

    3/5/26 7:01:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Liquidia Corp (0001819576) (Filer)

    3/5/26 6:45:34 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Monopar Therapeutics (0001645469) (Filer)

    3/2/26 8:01:10 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics downgraded by Raymond James

    Raymond James downgraded Monopar Therapeutics from Strong Buy to Outperform

    11/14/25 9:54:47 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Monopar Therapeutics with a new price target

    Leerink Partners initiated coverage of Monopar Therapeutics with a rating of Outperform and set a new price target of $115.00

    11/10/25 8:46:42 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CCSO Rodriguez Susan

    4 - Monopar Therapeutics (0001645469) (Issuer)

    3/4/26 5:25:43 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rodriguez Susan

    3 - Monopar Therapeutics (0001645469) (Issuer)

    3/4/26 5:25:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Schundler Russell converted options into 2,344 shares and sold $32,812 worth of shares (1,073 units at $30.58), increasing direct ownership by 0.21% to 614,057 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    3/3/26 4:34:52 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

    Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

    7/21/23 4:54:32 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

    Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

    11/18/21 2:49:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    Financials

    Live finance-specific insights

    View All

    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

    WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to di

    3/5/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

    WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a corporate update conference call on Tuesday, December 2, 2025 at 9:00am ET. The call will provide a corporate update, including recent clinical, regulatory, and operational developments. A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865. About NRx P

    12/2/25 7:30:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (NASDAQ:AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional ca

    11/19/25 6:00:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    Leadership Updates

    Live Leadership Updates

    View All

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

    Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has joined HOPE as Medical DirectorImmediate expansion is planned in Western Florida and Palm BeachAcquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), today announced the acquisition of a strategic interest in Cohen and Associates, LLC ("Cohen, LLC") and its incorporation into the HOPE Network. Additionally, Rebecca Cohen, MD has joined HOPE as Medical Dire

    10/20/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVDL
    $BJDX
    $CNCE
    $EVLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

    SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    11/26/24 4:15:26 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care